Physician profile
John D Bartges
NPI 1467484527
$1,152.60
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $216 · 2021: $115 · 2022: $21.54 · 2024: $26.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $26.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $26.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $301.57 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $189.12 | 2019-2020 | |
| Neotract INC. | $108.57 | 2019 | |
| Sun Pharmaceutical Industries INC. | $85.30 | 2019-2021 | |
| Janssen Biotech, INC. | $60.11 | 2019 | |
| Dendreon Pharmaceuticals LLC | $58.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.09 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $37.91 | 2020 | |
| Therapeuticsmd, INC. | $32.77 | 2019 | |
| Foundation Medicine, INC. | $30.07 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.61 | 2019-2020 | |
| Abbvie INC. | $26.50 | 2024 | |
| Boston Scientific Corporation | $21.54 | 2022 | |
| Rochester Medical Corporation | $19.68 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $17.73 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $17.71 | 2020 | |
| 180 Medical, INC. | $17.54 | 2019 | |
| Clovis Oncology, INC. | $13.59 | 2021 | |
| Olympus America INC. | $13.09 | 2021 | |
| Myriad Genetic Laboratories, INC. | $12.54 | 2021 | |
| Myovant Sciences INC. | $11.24 | 2021 | |
| Pfizer INC. | $11.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bartges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.